Affiliate disclosure: The RX Index earns a commission when you sign up with some of the providers mentioned on this page. It does not affect what you pay, and it never determines our rankings or which providers we cover. Read the full disclosure.

By The RX Index Editorial TeamLast verified: May 29, 2026Sources: CMS, KFF, TrumpRx, Ro, Medicare.gov — checked monthly

Medicare GLP-1 Bridge MFP: What You’ll Actually Pay in 2026–2027

Disclosure: Some links on this page are affiliate links. If you purchase through these links, we may earn a commission at no extra cost to you.

The short version

The Medicare GLP-1 Bridge and the MFP are two different things, and mixing them up can cost you hundreds of dollars a month.

The BridgeA short-term Medicare program (July 1, 2026 – Dec. 31, 2027) that lets eligible Part D members get Wegovy, the Zepbound KwikPen, or Foundayo for weight loss at a flat $50 a month — the same $50 no matter how high your dose goes.

The MFPA separately negotiated Medicare price for semaglutide (the ingredient in Ozempic, Rybelsus, and Wegovy) that takes effect January 1, 2027 — about $274 for a 30-day supply. That’s what Medicare pays the drugmaker, not your copay.

If you’re on Medicare, want a GLP-1 for weight loss, and qualify, the Bridge’s $50 copay is your cheapest path — full stop. The MFP won’t lower that $50; it’s a different lever for a different group of people.

That’s the headline. The reason this is so confusing — and why even news outlets keep getting it wrong — is that there are four different prices floating around for the same handful of drugs, plus a second government “Medicare price” that isn’t the MFP at all. We’ll untangle every piece, show you exactly what each drug costs on each path, and hand you the words to say to your doctor and your pharmacy.

This is a coverage and pricing guide, not medical advice. Qualifying for a program is not the same as a drug being right for you — your doctor makes that call.

Find your path ↓Get your free 60-second action plan →

What we actually verified (May 29, 2026)

This is the part most pages skip. Here’s what we checked and where it came from.

✓Bridge dates, drug list, $50 copay, eligibility rules, and pharmacy codes — confirmed word-for-word against the official CMS Medicare GLP-1 Bridge page (last updated May 6, 2026).
✓Extension to December 31, 2027 and the delay of the BALANCE program — confirmed against KFF’s policy brief (updated May 11, 2026).
✓MFP price and January 1, 2027 start date — from the CMS Medicare Drug Price Negotiation Program materials.
✓Self-pay prices — confirmed directly on TrumpRx and Ro on May 29, 2026. These deals change and some expire, so re-check before you buy.

We don’t run fake reviews, we don’t invent a “medical reviewer,” and we don’t pretend the MFP is your personal copay. Where the public record is still unsettled, we say so plainly.

The 4-track Medicare GLP-1 cost map

For weight loss, only Wegovy, the Zepbound KwikPen, and Foundayo get the $50 Bridge copay — and that flat $50 beats every cash price. Ozempic, Rybelsus, and Mounjaro aren’t weight-loss options on the Bridge, though regular Part D can cover them for diabetes, and the 2027 MFP lowers the price of the semaglutide drugs.

Monthly prices, rounded, verified May 29, 2026. On the insured paths, your exact out-of-pocket depends on your specific plan.

Drug	Bridge (weight loss, if you qualify)	Part D (approved diagnosis)	Self-pay, cash (TrumpRx / Ro / LillyDirect / NovoCare)
Wegovy — injection (pen)	$50/mo ✅ flat, any dose	Plan cost-share (covered for heart-disease risk; MFP base ≈ $386 from 1/1/27)	$199 to start → $349–$399
Wegovy — pill (oral)	$50/mo ✅ flat, any dose	Plan cost-share (semaglutide; MFP applies from 1/1/27)	$149 to start → $199–$299
Zepbound — KwikPen only	$50/mo ✅ flat, any dose	Plan cost-share (covered for sleep apnea, not weight loss)	$299 to start → $399–$449
Foundayo — oral pill	$50/mo ✅ flat, any dose	❌ N/A (no non-weight-loss approval yet)	$149 to start → $199–$299
Ozempic — injection	❌ Not on Bridge (diabetes drug)	Plan cost-share (covered for type 2 diabetes; MFP base ≈ $277 from 1/1/27)	Varies (off-label for weight loss)
Rybelsus — pill	❌ Not on Bridge	Plan cost-share (type 2 diabetes; MFP base ≈ $277 from 1/1/27)	Varies
Mounjaro — injection	❌ Not on Bridge	Plan cost-share (type 2 diabetes; not in this MFP round)	~$349–$499

·The Bridge is the cheapest path by a mile — if you qualify and you’re using the drug for weight loss.

·“Plan cost-share” counts toward your yearly cap. The $50 Bridge copay and all self-pay prices do not. That’s the one real catch, and we cover it in full below.

·The MFP is the price Medicare pays the drugmaker — not your copay. It lowers the underlying cost of the semaglutide drugs starting January 1, 2027, but it doesn’t set what you pay at the counter.

Sources: CMS, KFF, TrumpRx, Ro, LillyDirect, NovoCare — verified May 29, 2026.

Find your path in 60 seconds

Find the row that sounds like you.

If this is you…	Your most likely path	What to do next
Want a GLP-1 for weight loss, on a Part D plan, you meet a Bridge clinical route, and the drug is Wegovy, Zepbound KwikPen, or Foundayo	The $50 Bridge	Ask your doctor to submit a Bridge prior authorization (steps below)
Want it for weight loss but the drug is Ozempic, Mounjaro, or a Zepbound vial/pen	Bridge doesn’t cover that drug/form	Ask your doctor if a Bridge-covered drug fits — or compare self-pay
Using a GLP-1 for type 2 diabetes	Regular Part D	Use your plan's formulary; the MFP lowers the price from 1/1/27
Using Wegovy for heart-disease risk or Zepbound for sleep apnea	Regular Part D (not the Bridge)	Ask your plan about a formulary exception / prior authorization
Not on a Part D plan (only Part A & B)	No Bridge access yet	Check enrollment options at Medicare.gov, or self-pay for now
BMI under 27 / no qualifying condition	Likely not Bridge-eligible	Talk to your doctor; compare self-pay or other routes

Get your personalized GLP-1 action plan →

Not sure where you land? Our quiz walks you through it and builds a plan you can take to your doctor. Free, 60 seconds.

Medicare GLP-1 Bridge MFP: the one difference that changes your bill

The Bridge is about coverage — it lets Medicare pay for weight-loss GLP-1s it normally can’t, and charges you a flat $50. The MFP is about price — it lowers what Medicare pays drugmakers for semaglutide, mostly for diabetes and heart-disease use. They overlap on exactly one drug, Wegovy, and even then they apply to different uses.

The Bridge is a coverage workaround

By law, Medicare can’t pay for a drug used purely to lose weight. The Bridge is a temporary program that gets around that limit for three specific weight-loss drugs and charges you a flat $50. It exists because normal Medicare won’t cover these drugs for weight loss.

The MFP is a negotiated price

Under the Inflation Reduction Act, Medicare negotiated lower prices on expensive drugs. Semaglutide made the list. Starting January 1, 2027, that negotiated price kicks in. But the MFP is what Medicare pays the drugmaker — it doesn’t set your copay, and it doesn’t make Medicare cover anything it didn’t already cover.

→The Bridge answers: “Can I get a weight-loss GLP-1 through Medicare for $50?”

→The MFP answers: “What negotiated price applies to the semaglutide drugs in 2027?”

Where they overlap: Wegovy

Wegovy is the only drug in both programs. What you pay depends on why you’re taking it:

1Wegovy for weight loss → through the Bridge, you pay a flat $50. The MFP is irrelevant to your bill.

2Wegovy for heart-disease risk (an approved use) → through your regular Part D plan, and from 2027 the MFP becomes the negotiated base price (~$386), with your out-of-pocket set by your plan.

Zepbound and Foundayo are on the Bridge but are not in the MFP round (they’re tirzepatide and orforglipron — different ingredients). Ozempic and Rybelsus are in the MFP but not on the Bridge’s weight-loss list. CMS confirms: for 2026 the two programs “operate independently,” and no Bridge drug is subject to an MFP during the 2026 demonstration.

What is the Medicare GLP-1 Bridge?

The Medicare GLP-1 Bridge is a short-term CMS program running July 1, 2026 through December 31, 2027 that gives eligible Medicare Part D members a flat $50-a-month copay for certain GLP-1 weight-loss drugs. It “bridges” the gap before a longer-term program that may or may not start in 2028.

It covers three drugs, for weight loss.

When the drug is prescribed to lose excess weight and keep it off, the Bridge covers all forms of Wegovy (pen and pill), the Zepbound KwikPen only (the single-dose vial and single-dose pen are not included), and all forms of Foundayo. Foundayo was added in April 2026 after the FDA approved it.

The $50 doesn't go up with your dose.

You pay a flat $50 at the pharmacy — and it stays $50 even as you move to higher maintenance doses. That's a big deal. On cash plans, higher doses cost more; on the Bridge, the price is locked.

It runs on its own track — not your normal plan.

Even though you need Part D to qualify, the Bridge doesn't go through your regular plan's payment system. Your doctor sends the prescription and a prior authorization to a single central system run by Humana. Once approved, you pay your $50 at pickup. Behind the scenes, the drugmakers provide the drug at a net price of $245 a month, and the program covers the rest.

Already know you want the Bridge and just need the full eligibility and document checklist? See our deeper eligibility guide →

What the MFP is and when it changes your price

The MFP (Maximum Fair Price) is the Medicare-negotiated price for semaglutide under the Inflation Reduction Act, taking effect January 1, 2027 — about $274 for a 30-day supply of the Ozempic/Rybelsus/Wegovy group. It lowers what Medicare pays the drugmaker; your actual out-of-pocket still depends on your plan.

The MFP only applies to the drugs Medicare actually negotiated. In this round, that’s semaglutide: Ozempic, Rybelsus, and Wegovy. Tirzepatide (Zepbound, Mounjaro) and orforglipron (Foundayo) are not in this round — so the MFP doesn’t change their price at all.

CMS lists the three semaglutide products as one selected drug group with an agreed price of about $274 for a 30-day supply for 2027. The package-level examples vary a bit — roughly $276.78 for an Ozempic pen or a 30-day pack of Rybelsus, and about $385.63 for a Wegovy package — which is where the “$277 / $386” figures come from. That’s roughly 71% off the old ~$959 sticker price.

Why you’ve seen two different “Medicare prices”

This is the single most confusing part of the whole story. There are two separate government price efforts for these drugs:

IRA Maximum Fair Price (MFP)

About $274 for a 30-day supply, effective January 1, 2027 — from the formal drug-negotiation program. This is for the semaglutide drugs through regular Part D.

The MFN deal

A separate November 2025 deal with Novo Nordisk and Eli Lilly. That deal set the $245 net price behind the Bridge and powers the discounted self-pay prices on TrumpRx (trumprx.gov).

For your day-to-day math, it’s simpler than the headlines make it sound:

·Weight loss + Bridge → you pay $50

·Approved diagnosis + Part D → you pay your plan's cost-share (and it counts toward your cap)

·No insurance → you pay the self-pay price (below)

Does the MFP mean I’ll pay $274 or $386 for Wegovy, Ozempic, or Rybelsus?

No. The MFP is the negotiated price Medicare pays the drugmaker — it is not a guaranteed patient copay. What you actually pay still depends on your Part D plan’s deductible, your cost-sharing, and which phase of the benefit you’re in.

The MFP lowers the list price the system is built on. Your share is still set by your plan. Depending on your plan and where you are in the year, you might pay less than $274 (for example, after you hit your yearly cap) or a different amount based on your plan’s design. Treat the MFP as good news for the overall price of these drugs in 2027 — not as the number you’ll hand the pharmacist. If you want your real number, check your specific plan.

Which drugs are covered by the Medicare GLP-1 Bridge, and what does each cost?

For weight loss, only Wegovy, the Zepbound KwikPen, and Foundayo get the $50 Bridge copay. Ozempic, Rybelsus, and Mounjaro aren’t weight-loss options under the Bridge, though Part D can cover them for diabetes. Without insurance, FDA-approved GLP-1s run about $149 to $449 a month depending on the drug and dose.

Wegovy (semaglutide) — the best Bridge value, and the only drug in both programs.

Bridge + MFP

For weight loss through the Bridge: $50 flat. For heart-disease risk through Part D: your plan's cost-share, with the ~$386 MFP base from 2027. Self-pay: about $199 to start (lowest doses) and roughly $349–$399 after that for the injection, or about $149 to start and $199–$299 by dose for the pill.

Zepbound — KwikPen only (tirzepatide).

Bridge only

The single-dose vial and single-dose pen are not on the Bridge — that wording matters, so make sure your prescription is for the KwikPen. Self-pay runs about $299 to start and roughly $399–$449 by dose.

Foundayo (orforglipron) — the newest option, and a daily pill.

Bridge only

Covered by the Bridge at $50 for weight loss. It's not in the MFP round and has no non-weight-loss Medicare use yet, so outside the Bridge it's self-pay only (about $149 to start, $199–$299 by dose).

Ozempic & Rybelsus (semaglutide) — in the MFP, not on the Bridge.

MFP only

These are diabetes drugs. The Bridge won't give you $50 Ozempic for weight loss. But if you have type 2 diabetes, Part D covers them, and the 2027 MFP cuts the negotiated price to about $277.

Mounjaro (tirzepatide) — neither program helps directly for weight loss.

Neither

Part D covers Mounjaro for type 2 diabetes. It isn't a Bridge weight-loss drug and isn't in this MFP round. For weight loss, its sibling Zepbound (KwikPen) is the Bridge-eligible choice.

Do you qualify for the $50 Bridge copay?

To get the $50 Bridge copay you must be enrolled in an eligible Medicare Part D plan and meet one of three clinical routes, measured at the time you started GLP-1 therapy: a BMI of 35 or higher; a BMI of 30+ with certain heart or kidney conditions; or a BMI of 27+ with conditions like prediabetes, a prior heart attack, a prior stroke, or poor leg circulation. Your doctor confirms this in the prior authorization.

Gate 1 — Your plan

You need eligible Medicare drug coverage. CMS says you qualify if you’re enrolled in:

✓A standalone Part D drug plan (PDP), or
✓A Medicare Advantage plan that includes drug coverage (MA-PD) — an HMO, HMO-POS, or local/regional PPO.
✓Special Needs Plans (SNPs), employer/union group plans (EGWPs), and the LI NET program also qualify.
✓Dual-eligible beneficiaries (those with both Medicare and Medicaid) qualify too, as long as they're in an eligible plan type and meet the health rules.

A few plan types are generally not eligible — like private fee-for-service plans, certain cost-contract plans, and PACE. If you have only Part A and Part B (no drug coverage), you can’t use the Bridge until you have a Part D plan.

Gate 2 — Your health (the exact clinical rules)

Your doctor has to attest that the drug is for losing excess weight and keeping it off, along with ongoing lifestyle changes, and that you meet one of these three routes — measured at the time you started GLP-1 therapy:

Route	What it takes (age 18+)
1	BMI 35 or higher — qualifies on its own
2	BMI 30 or higher plus one of: heart failure with preserved ejection fraction (HFpEF), uncontrolled high blood pressure (over 140/90 despite two blood-pressure medicines), or chronic kidney disease stage 3a or higher
3	BMI 27 or higher plus one of: prediabetes, a previous heart attack, a previous stroke, or symptomatic peripheral artery disease (poor circulation in the limbs)

The rule that saves a lot of people: BMI is measured at the start

The BMI test is based on when you first started the medication — not today. So if you started a GLP-1 in 2024 at a BMI of 37 and you’ve since lost weight down to a BMI of 34, you can still qualify. Your doctor just attests that you met the BMI 35 rule when therapy began. Bring your old records if your current weight is lower; they’re your ticket in.

Build my Bridge checklist →

Want a clean checklist to hand your doctor? Our quiz builds one for you from your answers — no guesswork at the appointment.

How to actually get the $50 copay (step by step)

Confirm you’re in a Part D plan, ask your doctor whether you meet a Bridge route, have them submit a prior authorization to the central CMS/Humana system for Wegovy, the Zepbound KwikPen, or Foundayo, and once it’s approved you pay $50 at the pharmacy. The Bridge starts July 1, 2026.

Confirm your drug coverage.

Make sure you're in a Part D plan or an MA plan with drug coverage. Not sure? Medicare's own Plan Finder at Medicare.gov shows what you have, and you can call 1-800-MEDICARE for free help.

Ask your doctor about the Bridge.

Bring your current weight/BMI and any weight-related conditions. Be specific: ask about Wegovy, the Zepbound KwikPen, or Foundayo for weight loss under the Medicare GLP-1 Bridge. Your doctor does not have to be a Medicare-enrolled provider to do this.

Have the prior authorization submitted.

Your doctor sends the request and prescription to the central CMS/Humana system. This is the step that unlocks the $50.

Pick it up for $50.

Once it's approved, you pay the flat $50 at the pharmacy — and the same $50 every refill, even when your dose goes up.

Exactly what to say to your doctor

Save this and bring it with you:

“I’d like to know whether my GLP-1 should go through the Medicare GLP-1 Bridge or my regular Part D plan. The drug is [Wegovy / Zepbound KwikPen / Foundayo], and it’s for weight loss. My BMI when I started GLP-1 therapy was [BMI], and I have [any qualifying condition]. Can you submit the Bridge prior authorization and include my BMI-at-start in the request?”

Exactly what to say to the pharmacy

If the pharmacy treats it like a normal (rejected) Part D claim, this line fixes it:

“This was approved under the Medicare GLP-1 Bridge. CMS routes Bridge claims through BIN 028918, PCN MEDDGLP1BR — not regular Part D. Can you confirm the claim is going to the central processor?”

Those codes (BIN 028918 / PCN MEDDGLP1BR) are the Bridge’s specific billing address, straight from CMS. Bridge claims have to be submitted electronically — paper claims and “pay now, get reimbursed later” aren’t accepted — and most pharmacy staff won’t have run many Bridge claims early on, so having the codes ready can save you a second trip.

What are the honest catches with the Medicare GLP-1 Bridge?

The Bridge’s flat $50 copay does not count toward your yearly Part D out-of-pocket cap or deductible, and Extra Help (the low-income subsidy) can’t be applied to it. For most people paying full price for weight-loss GLP-1s, $50 flat still wins easily — but if you have a coverable diagnosis or rely on Extra Help, regular Part D may be the better route.

The $50 doesn't count toward your cap.

Normally, what you spend on covered drugs counts toward the Part D out-of-pocket maximum — $2,100 in 2026 (expected to rise to around $2,400 in 2027, though CMS hasn’t finalized that figure). Bridge copays sit outside that system, so they don’t push you toward that ceiling on your other medications.

Extra Help (Low-Income Subsidy) doesn't apply.

Extra Help — the program that gives some people $5–$10 copays on their covered drugs — can't be applied to Bridge drugs.

Manufacturer coupons and discount cards don't stack.

CMS says coupons and discount programs can't be applied to Bridge claims. Manufacturer savings cards also typically exclude people on Medicare or other government programs, so don't count on them.

Honest reframe: If you’re like the typical person searching this — paying full freight for a weight-loss GLP-1 with no coverage at all — then $50 flat, at any dose, is dramatically less than the $149 to $449 you’d pay any other way. A catch that costs you nothing if you weren’t going to hit the cap anyway isn’t really a catch. It’s fine print.

When would regular Part D actually beat the Bridge? When your GLP-1 is for a covered diagnosis — type 2 diabetes, heart-disease risk (Wegovy), or sleep apnea (Zepbound) — because then it goes through your plan, counts toward your cap, and can use Extra Help. If that’s you, don’t use the Bridge — ask your plan about a regular Part D prior authorization or formulary exception instead. CMS is clear on this: drugs prescribed for a covered Part D use don’t qualify for the Bridge.

Compare my Bridge vs. Part D path →

If the cap, Extra Help limit, or end date is your dealbreaker, our quiz routes you to the right path for your situation.

What if you don’t qualify for the Medicare GLP-1 Bridge (or want a drug it skips)?

Not qualifying doesn’t always mean no GLP-1. If you have diabetes, heart-disease risk, or sleep apnea, regular Part D may cover the drug. If no Medicare path fits, your remaining option is self-pay on FDA-approved brand drugs, which runs about $149 to $449 a month.

First, are you really a regular-Part-D case?

If your GLP-1 is for type 2 diabetes (Ozempic, Rybelsus, Mounjaro), heart-disease risk (Wegovy), or sleep apnea (Zepbound), regular Part D may cover it — no Bridge needed. Ask your plan.

Second, did you miss a Bridge detail?

Double-check: Are you in an eligible Part D plan? Is the drug Wegovy, the Zepbound KwikPen, or Foundayo? Did your doctor use your starting BMI, not today's? Small fixes reopen the door for a lot of people.

Third — if a Medicare path truly doesn't fit — compare self-pay the smart way.

For self-pay on brand-name GLP-1s, Ro Body (sponsored affiliate link, opens in a new tab) is a solid place to compare. Ro carries FDA-approved brand drugs including Wegovy, Zepbound, and Foundayo, and prices them the same as LillyDirect, NovoCare, and TrumpRx. Its medication prices start around $149/month for some options; the Ro Body membership (sponsored affiliate link, opens in a new tab) — coaching and care, billed separately from the drug — is $39 to start, then as low as $74/month with an annual plan paid upfront. If you want a second option with a broad branded menu, Sesame Care (sponsored affiliate link, opens in a new tab) is worth a look.

Two honest notes for Medicare readers: This is not the $50 Bridge — self-pay prices are higher, and they don’t count toward any Medicare cap. Coupons usually don’t work if you’re on Medicare or another government program, so don’t count on them. And compounded GLP-1s are not a Medicare Bridge substitute — for a Medicare audience comparing real brand prices, stick with the FDA-approved options.

Ro’s insurance help is for Ro’s own treatment path (cash-pay or your commercial insurance). It does not submit the Medicare Bridge prior authorization — that always goes through your doctor and the CMS/Humana system. Use Ro as a cash-pay or commercial-insurance backup, not as the Bridge.

Self-pay brand GLP-1s (not the Medicare Bridge)

Affiliate links. For readers paying cash — not for Medicare coverage or Bridge enrollment.

Compare self-pay prices on Ro →See Sesame Care GLP-1 options →

Self-pay prices right now (TrumpRx, NovoCare, LillyDirect)

Without insurance, FDA-approved GLP-1s run about $149–$399 for Wegovy, $299–$449 for the Zepbound KwikPen, and $149–$299 for Foundayo through TrumpRx, NovoCare, and LillyDirect, verified May 29, 2026. These are cash prices and don’t count toward any Medicare cap.

Drug	To start	After the intro period	Notes
Wegovy injection	$199/mo for the first two fills (0.25 mg & 0.5 mg, new patients, through 6/30/2026)	$349/mo (0.25–2.4 mg); $399/mo for Wegovy HD 7.2 mg	Per TrumpRx
Wegovy pill	$149/mo (1.5 mg & 4 mg; the 4 mg deal runs through 8/31/2026)	$199–$299/mo by dose	Per TrumpRx & Ro
Zepbound KwikPen	$299/mo (2.5 mg)	$399/mo (5 mg); $449/mo (7.5–15 mg)	Per Ro; matches LillyDirect
Foundayo	$149/mo	$199–$299/mo by dose	Per Ro; matches LillyDirect
Ozempic / Mounjaro	Varies	Varies	Off-label for weight loss; price varies by source

These prices don’t count toward any insurance cap, and they can be higher if you miss a refill or check-in window with the manufacturer offer. Intro deals also expire, so confirm the current price before you commit.

For a fuller cash-pay breakdown across providers: GLP-1 cost without insurance — full guide →

Should I use Medicare’s Plan Finder, my plan, Ro, or Sesame?

For Medicare coverage questions, start with official help — Medicare’s Plan Finder at Medicare.gov, 1-800-MEDICARE, your Part D plan, your doctor, or your free local SHIP counselor. Use a cash-pay comparison like Ro or Sesame only if you don’t qualify for the Bridge, need a non-Medicare backup, or are comparing FDA-approved brand prices.

Coverage questions

Medicare.gov Plan Finder, 1-800-MEDICARE, your plan's member line, your prescriber, or your SHIP (State Health Insurance Assistance Program — free, unbiased Medicare counseling in every state). These are the trustworthy, no-sales-pitch sources, and they're free.

The $50 Bridge

Always your doctor → the CMS/Humana system. No private company submits that for you.

Cash-pay on brand drugs (only if Medicare doesn't fit)

That's where Ro or Sesame earn a look, because they sell FDA-approved brand drugs at the drugmakers' prices and can handle their own paperwork. Just remember that's a separate, non-Medicare path.

What happens after December 31, 2027?

The Bridge is currently set to end December 31, 2027. It was meant to lead into a long-term program called the BALANCE Model, but that’s been indefinitely delayed in Part D after not enough insurers agreed to join. What replaces the Bridge in 2028 isn’t settled yet.

The original plan was a two-step approach: the Bridge first, then a permanent program (BALANCE) that would shift the cost to insurers. Not enough insurers signed on by the spring 2026 deadline, so CMS extended the Bridge instead — from six months to a full 18, now ending December 31, 2027. KFF’s Medicare experts note the extension is expensive for Medicare and that what comes next is genuinely uncertain.

Don’t assume the $50 copay lasts forever. If you start on the Bridge, plan a check-in with your doctor and your plan before the program ends. Keep your records (especially your starting BMI). Watch for CMS updates on BALANCE and on the 2027 details, since CMS has said more 2027 guidance is coming. We update this page monthly and will flag any change here.

Full detail on what comes after 2027: What happens after the Medicare GLP-1 Bridge ends → · CMS BALANCE Model explained →

A quick word on whether these drugs are right for you

Being eligible for coverage isn’t the same as being a good medical fit. Wegovy, Zepbound, and Foundayo all have FDA-approved labels with warnings and conditions where they shouldn’t be used. This page helps you ask better coverage questions — your doctor decides whether a GLP-1 is right for your body.

GLP-1s are powerful, and they’re not for everyone. Their FDA labels include serious warnings (for example, around a rare thyroid cancer risk and certain personal or family histories), plus common side effects that are mostly stomach-related. Older adults on Medicare often take several other medicines and may have kidney or hydration concerns that change the picture. When you talk to your doctor, ask: Do I have any reasons in the label not to take this? What side effects should make me call you? Could this interact with my other medicines? What’s the plan if I can’t tolerate it? Coverage gets you the drug; your doctor makes sure it’s the right one.

How we built this guide

The RX Index is a pricing intelligence and comparison resource for GLP-1 telehealth providers. For this guide we compared the official CMS Bridge rules, the CMS drug-negotiation materials, Medicare.gov Part D rules, FDA drug labels, and the drugmakers’ own pricing pages, then wrote it in plain English.

Our source order, highest first: CMS and Medicare.gov for the program rules and prices, FDA labels for safety, KFF for policy context, and the drugmakers’ own pages and TrumpRx for self-pay prices. We use provider pages (like Ro) only for their own pricing — never as the source for Medicare rules.

What you won’t find here: fake reviews, a made-up “medical reviewer,” star ratings we didn’t earn, any claim that the MFP equals your copay, any promise that the Bridge guarantees approval, or any blurring of compounded drugs with FDA-approved ones. If we couldn’t verify something, we marked it or left it out.

In KFF’s national polling, 56% of GLP-1 users said the drugs were hard to afford, including one in four who said “very hard.” If price has been the thing standing between you and a medication your doctor supports, you’re in very good company — and the Bridge exists precisely to fix that for the people who qualify.

Frequently asked questions

Is the Medicare GLP-1 Bridge the same as the MFP?

No. The Bridge is a short-term program (July 1, 2026 through December 31, 2027) giving eligible Part D members a flat $50/month copay for Wegovy, the Zepbound KwikPen, or Foundayo used for weight loss. The MFP is a separately negotiated Medicare price for semaglutide (Ozempic, Rybelsus, Wegovy) that starts January 1, 2027 and mainly applies when those drugs are used for an approved reason like diabetes or heart-disease risk.

Does the MFP lower my $50 Bridge copay?

No. CMS treats the two as separate programs, and the Bridge runs outside the regular Part D payment system. For 2026, no Bridge drug is subject to an MFP. Your Bridge copay stays $50 regardless of the MFP.

Does the MFP mean my copay will be $274?

No. The MFP is the price Medicare pays the drugmaker, not your personal copay. Your out-of-pocket still depends on your Part D plan's deductible, your cost-sharing, and where you are in the benefit year.

How much will Wegovy or Zepbound cost me on Medicare?

If you qualify for the Bridge and use it for weight loss, you pay a flat $50/month for Wegovy, the Zepbound KwikPen, or Foundayo at any dose. If you use a drug for an approved diagnosis through regular Part D, you pay your plan's cost-share, and from January 1, 2027 the MFP lowers the underlying semaglutide price (about $277 for Ozempic/Rybelsus, $386 for Wegovy), though your out-of-pocket depends on your plan.

Who qualifies for the $50 Medicare GLP-1 copay?

You must be in an eligible Medicare Part D plan (a standalone PDP or an MA plan with drug coverage; SNPs, EGWPs, and LI NET also count), and you must meet one clinical route measured at the time you started the drug: BMI 35+; or BMI 30+ with HFpEF, uncontrolled high blood pressure, or kidney disease stage 3a+; or BMI 27+ with prediabetes, a prior heart attack, a prior stroke, or symptomatic peripheral artery disease. Your doctor attests to this in a prior authorization.

Does the Bridge cover Ozempic?

No. The Bridge covers Wegovy (all forms), the Zepbound KwikPen, and Foundayo for weight loss. Ozempic and Rybelsus are not on the Bridge weight-loss list, but Part D can cover them for type 2 diabetes, and the 2027 MFP lowers their negotiated price to about $277.

Does the Bridge cover Zepbound?

Only the Zepbound KwikPen. The single-dose vial and single-dose pen are not covered by the Bridge, so make sure your prescription is written for the KwikPen.

Does the $50 Bridge copay count toward my Part D out-of-pocket cap?

No. The Bridge runs outside the regular Part D system, so the $50 copay does not count toward your $2,100 (2026) out-of-pocket cap or deductible. The low-income subsidy (Extra Help) also cannot be applied to it.

Can I use a manufacturer coupon with the Bridge?

No. CMS says coupons and discount programs cannot be applied to Bridge claims, and manufacturer savings cards typically exclude people on Medicare or other government programs.

Can I start before July 1, 2026 and still qualify?

The Bridge itself starts July 1, 2026, but the clinical rules are based on your BMI when you started GLP-1 therapy, including therapy started before Medicare or before the Bridge launched. Earlier treatment can help you qualify.

What happens after 2027?

The Bridge is set to end December 31, 2027. The long-term replacement (the BALANCE Model) has been indefinitely delayed in Part D, so what happens in 2028 is not yet settled. Plan a continuity conversation with your doctor and plan before the program ends.

Still not sure which GLP-1 program is right for you?

You don’t have to figure this out alone, and you definitely shouldn’t overpay because the rules are confusing. Take our free 60-second matching quiz and get the exact words to bring to your doctor.

Get your personalized GLP-1 action plan →

Related guides

Sources

The RX Index is a pricing intelligence and comparison resource for GLP-1 telehealth providers. This article is general information about Medicare coverage and drug pricing. It is not medical advice, insurance advice, or a guarantee of coverage; rules and prices change, and your plan and your doctor are the final word on your situation. Some links are affiliate links, and we may earn a commission at no extra cost to you — this never affects our coverage recommendations. Last verified: May 29, 2026.